Trained as a molecular and cellular immunologist, I joined Pharmacia (legacy GD Searle/Monsanto) Discovery Research to help design effective antigen constructs for dendritic cancer vaccines. This led to work on the discovery and preclinical proof-of-concept studies of therapeutic antibodies for oncology. When Pharmacia merged with Pfizer, I moved into the inflammation therapeutic area where I led projects on chemokine receptor antagonism (small and large molecule) and shuttling therapeutic antibodies, against various soluble and cell-bound targets, into first-in-human/patient clinical trials. In 2010, I transitioned my career with a move to Analytical R&D in Pfizer’s Biotherapeutics Pharmaceutical Science (BioTx PS) division. This move allowed me to focus on candidates in clinical development and licensure stages. In BioTx PS, I have worked on complex bioassays for many modality-types and led global analytical teams in the areas of Vaccines and Gene Therapy. This work involves the development of the analytical strategy and implementation for both early and late phase projects. My current focus is advancing viral therapeutics for critical unmet needs with accelerated timelines.